Press enter to see results or esc to cancel.

Cytoki Pharma

Cytoki Pharma is engaged in the development of protein drugs for diseases characterized by epithelial injury. To that end, the company is advancing a long-acting Interleukin-22 (IL-22) variant to clinical testing with the initial focus on Inflammatory Bowel Disease (IBD). The lead compound is selected from a full program of therapeutic IL-22 variants based on …

Continue Reading